January 9, 2023
QULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults
November 23, 2022
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn’s Disease
No current content.